MDPI and ACS Style
Schultheis, B.; Strumberg, D.; Kuhlmann, J.; Wolf, M.; Link, K.; Seufferlein, T.; Kaufmann, J.; Feist, M.; Gebhardt, F.; Khan, M.;
et al. Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/IIa Study. Cancers 2020, 12, 3130.
https://doi.org/10.3390/cancers12113130
AMA Style
Schultheis B, Strumberg D, Kuhlmann J, Wolf M, Link K, Seufferlein T, Kaufmann J, Feist M, Gebhardt F, Khan M,
et al. Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/IIa Study. Cancers. 2020; 12(11):3130.
https://doi.org/10.3390/cancers12113130
Chicago/Turabian Style
Schultheis, Beate, Dirk Strumberg, Jan Kuhlmann, Martin Wolf, Karin Link, Thomas Seufferlein, Joerg Kaufmann, Mathilde Feist, Frank Gebhardt, Mike Khan,
and et al. 2020. "Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/IIa Study" Cancers 12, no. 11: 3130.
https://doi.org/10.3390/cancers12113130
